Vettore is a clinical-stage drug development company that has identified a novel small molecule used to inhibit the MCT4 protein in order to change the cell behaviors that lead to fibrosis in the lungs of patients suffering from Idiopathic Pulmonary Fibrosis. Vettore is also exploring the possibility that similar therapeutic mechanisms might be applicable to other diseases.

OMVax is a pre-clinical vaccine development company with a novel meningococcal vaccine. The vaccine consists of native outer membrane vesicles that have been genetically modified to be more effective using OMVax’s proprietary technology. This vaccine is potentially more broadly protective against group B strains, which cause the majority of disease in developed countries. OMVax is also using the technology to develop vaccines to protect against gonorrhea and syphilis, for which no vaccines are currently available.

Ilytica is an image based digital molecular analytics company focused on developing microdrop assays for diagnostic and analytic purposes. Ilytica’s unique and patented technology leverages machine learning to produce extremely error resistant molecular assays that are fast and easy to use.

For more information, visit ilytica.com